Home > Insider Trading > Filing (0000899243-17-028694)

Filing Details

Accession Number:: 0000899243-17-028694
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-12-14 16:09:47
Reporting Period:: 2017-12-12

Accepted Time:: 2017-12-14 16:09:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1281933	K Douglas Bratton	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1536054	Crestline Management, Lp	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1626596	Crestline Investors, Inc.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1626597	Crestline Si (Gp), L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1716958	Akdl, L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723783	Bratton Capital Inc.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723787	Bratton Capital Management, L.p.	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No
1723842	Neuro Line Partners Lp	201 Main Street, Suite 1900 Fort Worth TX 76102	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-12-12	14,499,999	$0.00	14,812,499	No	4	C	Indirect	By AKDL, L.P.
Common Stock	Acquisiton	2017-12-12	2,500,000	$0.00	17,312,499	No	4	C	Indirect	By AKDL, L.P.
Common Stock	Acquisiton	2017-12-12	1,875,000	$0.00	19,187,499	No	4	C	Indirect	By AKDL, L.P.
Common Stock	Acquisiton	2017-12-12	743,599	$0.00	743,599	No	4	C	Indirect	By Neuro Line Partners, L.P.
Common Stock	Acquisiton	2017-12-12	128,200	$0.00	871,799	No	4	C	Indirect	By Neuro Line Partners, L.P.
Common Stock	Acquisiton	2017-12-12	240,000	$0.00	1,111,799	No	4	C	Indirect	By Neuro Line Partners, L.P.
Common Stock	Acquisiton	2017-12-12	275,000	$18.00	19,462,499	No	4	P	Indirect	By AKDL, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By AKDL, L.P.
No	4	C	Indirect	By AKDL, L.P.
No	4	C	Indirect	By AKDL, L.P.
No	4	C	Indirect	By Neuro Line Partners, L.P.
No	4	C	Indirect	By Neuro Line Partners, L.P.
No	4	C	Indirect	By Neuro Line Partners, L.P.
No	4	P	Indirect	By AKDL, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-12-12	14,499,999	$0.00	14,499,999	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-12-12	2,500,000	$0.00	2,500,000	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2017-12-12	1,875,000	$0.00	1,875,000	$0.00
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-12-12	743,599	$0.00	743,599	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-12-12	128,200	$0.00	128,200	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2017-12-12	240,000	$0.00	240,000	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the "Issuer") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL.
(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line.
(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.